Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2020-04-27 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
第六届监事会第七次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the seventh meeting of the sixth Supervisory Board of 嘉事堂药业股份有限公司, held on April 27, 2020. It includes approvals of various reports and proposals related to the 2019 fiscal year, such as the Supervisory Board's 2019 work report, 2019 business summary, internal control self-evaluation report, financial statements audited by Ernst & Young Hua Ming, profit distribution plan, social responsibility report, and other governance and operational matters. The document also references that these reports will be submitted to the shareholders' meeting for approval and provides links to the full reports on the official disclosure platform. The content is primarily about board/management oversight and approvals rather than the full annual report itself. The document is an official announcement of board resolutions and supervisory board decisions, which fits the category of Board/Management Information (MANG). The document length is 4075 characters, which is substantial and contains detailed content, not just a brief announcement or a certification letter, so it is not RNS or RPA. Therefore, the best classification is MANG with high confidence.
2020-04-27 Chinese
独立董事关于第六届董事会第七次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from the independent directors of 嘉事堂药业股份有限公司 providing their prior approval opinions on several matters to be discussed at the company's sixth board of directors' seventh meeting. The matters include the 2019 profit distribution plan, 2020 daily related-party transactions, reappointment of the accounting firm for 2020 audit services, and amendments to the company's related-party transaction management measures. The document references compliance with relevant laws, regulations, and company articles, and it is signed by all independent directors. The content is focused on governance and board-level approvals rather than financial results, earnings, or audit reports. It does not contain financial statements or detailed financial data but rather opinions and approvals related to governance and board decisions. Therefore, this document fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management, including approvals and opinions from independent directors on board matters.
2020-04-27 Chinese
第六届董事会第七次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the sixth board of directors' seventh meeting of 嘉事堂药业股份有限公司, held on April 27, 2020. It includes approvals of various reports such as the 2019 Board Work Report, 2019 Internal Control Self-Evaluation Report, 2019 Financial Final Report, 2019 Profit Distribution Plan, 2019 Social Responsibility Report, and others. The document also mentions that these reports will be submitted to the shareholders' meeting for approval and provides links to where the full reports can be found. The document is not the reports themselves but a formal announcement of the board meeting decisions and approvals. The length is 4614 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement of board meeting resolutions and references to reports rather than the reports themselves.
2020-04-27 Chinese
关于续聘会计师事务所的公告
Audit Report / Information Classification · 90% confidence The document is an announcement regarding the reappointment of the auditing firm Ernst & Young Hua Ming LLP for the company's 2020 annual audit services. It details the auditor's qualifications, experience, and the approval process by the board and independent directors. The document does not contain any actual financial statements or audit results, but rather informs shareholders and the public about the intention to continue the auditor engagement, pending shareholder approval. The document length is 2529 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR) because it relates specifically to audit firm appointment and audit service information, but it is not a full annual report or audit report itself. However, given the short length and nature as an announcement of auditor reappointment, it aligns more closely with Audit Report / Information (AR) rather than a full Annual Report (10-K) or Regulatory Filing (RNS). FY 2020
2020-04-27 Chinese
第六届监事会第七次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the seventh meeting of the sixth Supervisory Board of 嘉事堂药业股份有限公司, held on April 27, 2020. It includes approvals of various reports and proposals related to the 2019 fiscal year, such as the Supervisory Board's 2019 work report, 2019 business summary, internal control self-evaluation report, financial statements audited by Ernst & Young Hua Ming, profit distribution plan, social responsibility report, and other governance and operational matters. The document also references that these reports will be submitted to the shareholders' meeting for approval and provides links to the full reports on the official disclosure platform. The content is comprehensive and includes substantive financial data and management oversight information, indicating it is a management/board-related report rather than a simple announcement or certification. It is not a full annual report (10-K) but rather a supervisory board meeting resolution document covering multiple governance and financial oversight topics. Therefore, the best fitting category is Board/Management Information (MANG). The document length is 4075 characters, which is sufficient for detailed content rather than a brief announcement. Hence, classification as MANG is appropriate with high confidence.
2020-04-27 Chinese
2019年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2019 年年度报告摘要" which translates to "2019 Annual Report Summary". It contains detailed financial data for the year 2019, including revenue, net profit, earnings per share, and changes in accounting policies. It also discusses business operations, industry position, shareholder information, and changes in consolidated subsidiaries. The length of the document (over 12,000 characters) and the presence of comprehensive financial and operational data indicate this is a substantive report, not merely an announcement or summary notice. The content aligns with the characteristics of an Annual Report (10-K) as it covers company activity and full financial performance for the fiscal year. Therefore, the appropriate classification is Annual Report (10-K). FY 2019
2020-04-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.